Douglas Miehm
Stock Analyst at RBC Capital
(3.59)
# 872
Out of 5,050 analysts
49
Total ratings
52.38%
Success rate
7.06%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $14.61 | +2.67% | 11 | Nov 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $7 → $8 | $5.63 | +42.10% | 3 | Aug 26, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.65 | +50.38% | 21 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $15.55 | +9.32% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.02 | +390.20% | 1 | Mar 10, 2025 |
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $14.61
Upside: +2.67%
MannKind
Aug 26, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.63
Upside: +42.10%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.65
Upside: +50.38%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $15.55
Upside: +9.32%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.02
Upside: +390.20%